Details for Patent: 10,201,517

Which drugs does patent 10,201,517 protect, and when does it expire?

Patent 10,201,517 protects MIRVASO and is included in one NDA.

This patent has thirty-four patent family members in twenty-six countries.

Summary for Patent: 10,201,517

Scope and claims summary:

Title:	Brimonidine gel compositions and methods of use
Abstract:	Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.
Inventor(s):	Buge; Jean-Christophe (Nice, FR), Nadau Fourcade; Karine (Villeneuve Loubet, FR), Meunier; Cyril (St. Raphael, FR)
Assignee:	Galderma Laboratories, L.P. (Fort Worth, TX)
Application Number:	15/220,501
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound;

Drugs Protected by US Patent 10,201,517

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	AB	RX	Yes	Yes	10,201,517		Y

Foreign Priority and PCT Information for Patent: 10,201,517

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	10 58612	Oct 21, 2010

International Family Members for US Patent 10,201,517

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	083651
Australia	2011317554
Brazil	112013009578
Canada	2814952